

Collaboration with and support by Orion Pharma marketing organisations to patient organisations in 2025

By country, in alphabetical order

COUNTRY / SUBSIDIARY NAME	TYPE OF SUPPORT	VALUE EUR
Australia: Orion Pharma (Aus)	To: National Asthma Council • Corporate sponsorship of the Asthma Medication Chart • Support for National Prescribing Guidelines • Support for asthma education in the community	€ 14,000
	To: Asthma Australia • Corporate sponsorship and support of asthma patient education through Asthma Action Plans distributed by the Orion field team • Corporate sponsorship of the "Know Your Options" asthma education and awareness campaigns	€ 11,000
Austria: Orion Pharma (Austria) GmbH	No collaboration or support in 2025	
Belgium: Orion Pharma BVBA/SPRL	No collaboration or support in 2025	
Czech Republic: Orion Pharma s.r.o.	No collaboration or support in 2025	
Denmark: Orion Pharma A/S	No collaboration or support in 2025	
Estonia: OÜ Orion Pharma Eesti	No collaboration or support in 2025	
Finland: Orion Corporation, Orion Pharma	To: Allergia-, Iho- ja Astmaliitto ry • Research collaboration on the Asthma and Allergy Barometer • Two advertisements in membership magazine	€ 18,000
	To: Hengitysliitto	€ 6,400

Orion Corporation

Registered office and domicile:

Orionintie 1
FI-02200 Espoo, Finland
P.O.Box 65
FI-02101 Espoo, Finland

Tel. +358 10 4261

www.orionpharma.com

Tengströminkatu 8
FI-20360 Turku, Finland
P.O.Box 425
FI-20101 Turku, Finland

VAT Reg. Business
Identity Code FI19992126

Volttikatu 8
FI-70700 Kuopio, Finland
P.O.Box 1780
FI-70701 Kuopio, Finland

		<ul style="list-style-type: none"> • Exhibition space at the Respiratory Days • Supporting membership fee To: Diabetesliitto ry • Membership fee • 4 advertisements in membership magazine To: Neuroliitto • 2 advertisements in membership magazine To: Psoriasisliitto ry • Advertisement in membership magazine To: Suomen Aivot ry • Membership fee To: Suomen Dystoniayhdistys ry • Exhibition booth fee and support for the Dystonia Days • Website advertising and newsletters To: Liikehäiriösairauksien liitto ry • Membership fee • Advertisements in membership magazine • Logo advertisement in webinar To: Suomen Kilpirauhasliitto ry • 4 advertisements in membership magazine To: Epilepsialiitto ry • Membership fee To: Suomen Nivelyhdistys ry • Membership fee To: Young Tongues, UK • Consulting services related to sharing patient experiences of living with tongue cancer • Recording and use of patient experience materials for educational purposes and community support 	<p>€ 4,000</p> <p>€ 1,500</p> <p>€ 6,700</p> <p>€ 13,440</p> <p>€ 3,488.47</p> <p>€ 3,650</p> <p>€ 1,000</p> <p>€ 600</p> <p>€ 300</p> <p>€ 2,000</p> <p>€ 4,400</p> <p>€ 500</p> <p>€ 4,250</p> <p>€ 5,000</p> <p>€ 800</p> <p>€ 1040</p>
France: Orion Pharma SA		<ul style="list-style-type: none"> To: France Parkinson • Subvention for Parkinson World Day activities in France • Support for a webinar related to Parkinson awareness To: La Voix des Migraineux • Subvention for the National Migraine Summit in France 	<p>€ 12,000</p> <p>€ 7,000</p>
Germany: Orion Pharma GmbH		<ul style="list-style-type: none"> To: Arbeitsgemeinschaft Allergiekranke Kind – Hilfen für Kinder mit Asthma, Ekzem oder Heuschnupfen (AAK) e.V. • Participation in a round-table discussion on the carbon-neutral patient pathway for asthma and COPD within Public Affairs activities 	<p>€ 0</p>

Greece: Orion Pharma Hellas		No collaboration or support in 2025	
Hungary: Orion Pharma Kft.		No collaboration or support in 2025	
Ireland: Orion Pharma (Ireland) Ltd.		No collaboration or support in 2025	
Italy: Orion Pharma S.r.l.		No collaboration or support in 2025	
Japan: Orion Pharma Japan K.K.		No collaboration or support in 2025	
Kazakhstan: Orion Pharma East LLP		No collaboration or support in 2025	
Latvia: Orion Pharma Latvia Representative Office		No collaboration or support in 2025	
Lithuania: UAB Orion Pharma		No collaboration or support in 2025	
Malaysia: Orion Pharma (MY) Sdn. Bhd		No collaboration or support in 2025	
Netherlands:		No collaboration or support in 2025	
New Zealand: Orion Pharma (NZ) Ltd,		To: Parkinson's New Zealand <ul style="list-style-type: none"> • Advertisement in the national newsletter • Honoraria payment to a neurology speaker at a Parkinson's New Zealand educational event 	€ 508 (NZD 1,000) € 508 (NZD 1,000)
Norway: Orion Pharma AS		No collaboration or support in 2025	
Poland: Orion Pharma Poland Sp. z.o.o.		No collaboration or support in 2025	

Click or tap here to enter text.

[Document name]

[Subtitle]

[Date]

Portugal: Orionfin Unipessoal Lda		To: Migra Portugal <ul style="list-style-type: none">• Awareness campaign "Com a enxaqueca, nunca sabes o que te calha na rifa!"	€ 2,500
Singapore: Orion Pharma (SG) Pte. Ltd.		No collaboration or support in 2025	
Slovakia: Orion Pharma s.r.o.		No collaboration or support in 2025	
Slovenia: Orion Pharma d.o.o.		No collaboration or support in 2025	
Spain: Orion Pharma S.L.		No collaboration or support in 2025	
Sweden: Orion Pharma AB		To: Schizofreniförbundet <ul style="list-style-type: none">• Support for the layout and printing of a support handbook for telephone counselling• Printing of 1,400 copies of the handbook (the Association will retain rights to 800 copies; Orion Pharma will have access to 600 copies)	€ 5,428 (SEK 57,200)
Switzerland: Orion Pharma AG		No collaboration or support in 2025	
Thailand: Orion Pharma Thai Co., Ltd.		No collaboration or support in 2025	
Ukraine: Orion Pharma Ukraine		No collaboration or support in 2025	
United Kingdom: Orion Pharma (UK) Ltd.		To: Asthma + Lung UK <ul style="list-style-type: none">• Support for collaboration with the Asthma + Lung UK taskforce for lung health• Participation in an industry collaboration group enabling input and joint activities	€ 11,500
USA: Orion Pharma, Inc.		No collaboration or support in 2025	